Reglagene, NeuroEM, Avery Therapeutics, and OncoMyx Therapeutics will deliver Company Presentations given by senior-level executives at the 2022 BIO International Convention in San Diego. Company Presentations showcase a company’s pipeline, R&D activities, business objectives, and investment goals.
Monday, June 13, 2022
2:45 – 3:00 PM – Reglagene – Company Theater 4
Reglagene is an oncology biotechnology company focused on developing novel medicines for difficult to treat and metastatic cancers. For example, only 4 of the 217 FDA approved cancer medicines are indicated for high-grade glioma (HGG). The best of the four, temozolomide, only extends life by 2.5 months. Cancer medicines struggle to pass into the brain, and the ones that do are toxic and ineffective. This forces patients to choose between palliative care and brief extended survival with major loss of their quality of life. The team at Reglagene is combating this unmet medical need by developing a therapeutically effective, orally administered, blood-brain barrier penetrant cancer medicine aiming to extend life and the improve the quality of life of those suffering from HGG. Although, the clinical relevance of Reglagene’s cancer medicine doesn’t end with HGG. We have shown a broad range of efficacy in multiple cancers that frequently metastasize to the brain. Add to Calendar
Tuesday, June 14, 2022
11:30- 11:45 AM – NeuroEM – Company Theater 1
NeuroEM is a clinical-stage company that has received FDA “Breakthrough” designation for its wearable MemorEM device for the treatment of cognitive decline in patients with Alzheimer’s Disease. MemorEM delivers Transcranial Electromagnetic treatment, (“TEMT”) Add to Calendar
Wednesday, June 15, 2022
2:30 – 2:45 PM – Avery Therapeutics – Company Theater 1
Avery Therapeutics is a preclinical-stage company, developing advanced therapies for patients suffering from cardiovascular diseases, with the vision of being a leader in next-generation bioengineered therapeutics. Avery’s mission is to develop innovative treatments to address large unmet medical needs and improve human quality of life. Avery’s lead candidate is a tissue engineered cardiac graft, MyCardia™, in development for treatment of chronic heart failure. Add to Calendar
4:15 – 4:30 PM – OncoMyx Therapeutics – Company Theater 3
OncoMyx Therapeutics is advancing oncolytic immunotherapies with the goal of achieving the greatest therapeutic benefit for more cancer patients. Successful immuno-oncology cancer treatment generally requires combination therapy, and oncolytic viruses have the potential to be a safe and effective complement to immunotherapies. OncoMyx has assembled the top immuno-oncology team to develop oncolytic immunotherapies based on the myxoma virus platform to orchestrate an immune response with the goal of better treating a wide range of cancers. The company’s myxoma virus platform is poised to be a best-in-class oncolytic virus approach and was developed based on breakthrough research from Dr. Grant McFadden’s lab that was exclusively licensed from Arizona State University. For more info, visit www.oncomyx.com. Add to Calendar